Mogrify appoints Dr Jonathan Appleby as Chief Scientific Officer
Strategic hire bolsters executive leadership team as Company progresses multiple therapeutic programs toward and into clinical development.
Mogrify extends Series A financing to $46 million USD
Cambridge, UK: Mogrify, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announces an additional $10 million USD closing of its Series A financing, bringing the total raised to $46 million USD in this round. The funding will support further advancement of Mogrify’s pipeline of in vivo reprogramming therapies through pre…
Mogrify appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor
Mogrify Limited (Mogrify®), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, today announced the appointment of Tom Graney CFA as Non-Executive Director, Audit Chair and Capital Markets Advisor.
Mogrify strengthens Executive Leadership Team with appointment of Louise Modis as Chief Scientific Officer
Mogrify Limited (Mogrify®), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, today announced the appointment of Dr Louise Modis as Chief Scientific Officer, following the recent completion of a $33 million USD Series A funding.
Mogrify completes Series A financing totalling $33 million
Mogrify Limited (Mogrify®), a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, announced today the second closing of its Series A financing of $17 million USD, bringing the total raised to $33 million in this round. The funding will support the advancement of Mogrify’s immuno-oncology and…
Double win for Mogrify at CambridgeshireLive Business Excellence Awards 2020
Mogrify wins Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at CambridgeshireLive Business Excellence Awards 2020. The awards recognise the potential of Mogrify’s technology to accelerate the development of regenerative cell and in vivo reprogramming therapies.
Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology
Mogrify Limited, a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, and the MRC Laboratory of Molecular Biology (LMB), a world-class research laboratory dedicated to understanding important biological processes at the molecular level, today announced an exploratory research collaboration.
Mogrify solidifies IP position surrounding core technology and expands platform algorithm to enhance cell conversion
Mogrify Limited (Mogrify®), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, today announced it had secured the assignment of the foundational intellectual property (IP) underpinning its core direct cell conversion technology (MOGRIFY® V1) and extended the method to allow for the inclusion of new sources of data…
Mogrify expands Scientific Advisory Board
Leaders in stem cell research and cell therapy to help drive development of scalable off-the-shelf therapies for diseases with a high unmet clinical need.
Mogrify introduces EpiMOGRIFY platform to systematically identify epigenetic switches driving cell identity and cell maintenance
Today Mogrify announced the introduction of EpiMOGRIFY. The platform models the epigenetic state of the cell to predict the switches important for cell identity, cell maintenance, directed differentiation and cell conversion.
Mogrify wins Life Science Innovation Award and Prof. Julian Gough named Academic Entrepreneur of the Year at Business Weekly Awards 2020
Mogrify Limited, a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, today announced it has won the AstraZeneca Life Science Innovation category of the 'Business Weekly' Awards.
Mogrify adds Dr Lorenz Mayr to Board of Directors and Scientific Advisory Board
Mogrify Ltd (Mogrify®), a UK biotechnology company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, today announced the appointment of Lorenz Mayr, PhD, to the Board of Directors and the Scientific Advisory Board (SAB).
Mogrify and Sangamo announce collaboration and exclusive licence agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells
Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics, a genomic medicine company, today announced that they have executed a collaboration and exclusive licence agreement for Sangamo to develop allogeneic cell therapies from Mogrify’s proprietary induced pluripotent stem cells …
Mogrify awarded $1.1M additional funding from SBRI Healthcare
Mogrify Ltd (Mogrify™), a UK company aiming to transform the development of cell therapies, today announced that it has secured $1.1M of additional funding from SBRI Healthcare, the NHS England funded initiative championed by the Academic Health Science Network (AHSN), to assess its regenerative cartilage therapy, for the treatment of cartilage defects, osteoarthritis and other musculoskeletal…
Mogrify wins Innovation Award and Dr Jane Osbourn OBE receives Lifetime Achievement Award at Scrip Awards 2019
Mogrify Ltd, a UK company aiming to transform the development of cell therapies, received MSD’s Innovation Award at the 15th Annual Scrip Awards, and the Lifetime Achievement Award was presented to Dr Jane Osbourn, OBE, Chair at Mogrify.
Mogrify wins 'Seed Stage Finance Raise of the Year' at 2019 European Lifestars Awards
Mogrify Ltd, a UK company aiming to transform the development of cell therapies, is pleased to announce that it has been recognised as the winner of the Seed Stage Finance Raise of the Year award at the 2019 Lifestars AwardsTM.
Mogrify named ‘The One to Watch’ at Cambridge Independent Science and Technology Awards 2019
Mogrify Ltd, a UK company aiming to transform the development of cell therapies, was named ‘The One to Watch’ at the Cambridge Independent Science and Technology Awards 2019. The award recognises the potential of their proprietary direct cellular conversion technology, enabling any mature adult cell to be transformed into any other, without going through a pluripotent stem cell or progenitor cell…
Mogrify raises additional $16 million to advance its mission to transform the development of life-saving cell therapies
Mogrify Ltd, a UK company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over $20 million USD to date.
Mogrify appoints Dr Jane Osbourn, OBE as Chair
Mogrify Ltd, a UK company aiming to transform the development of cell therapies, today announced the appointment of Dr Jane Osbourn, OBE as Chair of the Board. In addition to this role, Dr Osbourn will become a Member of the Scientific Advisory Board and support the Company’s executive team in therapeutic programme selection, industrial partner development, mentoring and investor relations.
Mogrify hosts careers open day at Bio-Innovation Centre, Cambridge Science Park
Mogrify Ltd, a company aiming to transform the future development of cell therapies, announced it will host a careers day at the Bio-Innovation Centre, 25 Cambridge Science Park on Friday, 16th August 2019 from 4–6pm. The event will showcase careers in the biotech industry, specifically in cell therapy and regenerative medicine, and offer attendees the opportunity to visit the Company’s research…
Mogrify awarded £420,000 Innovate UK funding to accelerate regenerative cell therapies
Project to focus on data-driven cell conversions to produce cell therapies with potential application in wound healing, and oncology immunotherapy
Mogrify raises $3.7m seed funding to transform cell therapy via direct cellular conversion
Cell Mogrify Ltd, a UK company aiming to transform the future development of cell therapies, today announced a second close on its seed funding, bringing the total raised to $3.7 million USD, and the appointment of Darrin M Disley, PhD, DSc, OBE, as CEO.